Sequencing of tumor biopsies is rapidly becoming the standard of care. While this type of profiling can identify actionable gene mutations or target gene expression, care is currently limited by a lack of targeted therapeutics.
Many drug developers are using these data to identify people more likely to respond to their therapies. We are using patient data to identify treatment gaps and design new-to-world therapies built for high success rates.
Aclys builds antibodies optimized for precision development. Aclys uses molecular profiling data from tens of thousands of cancer patients to build antibody-based precision therapeutics.
The resultant therapeutics are designed to have greater efficacy and safety, enable highly powered clinical trials with 1/10th the enrollees and cost, and have a much faster path to market than industry averages.
What We Do
Aclys employs a combination of computational methods and rational design, informed by the tumor profiles of >30,000 cancer patients.
Antibody Discovery / Optimization
Aclys’s proprietary mammalian cell-based discovery and optimization platform yields antibodies of the highest quality on an accelerated timeline.
Fully integrated high speed antibody expression and proof-of-concept assays, including our in vitro and in vivo evaluation.
Aclys collaborates with the world’s leading drug developers to maximize the impact of our pipeline.
Aclys Bio discovers and develops precision biologics for the treatment of cancer.